During the past decade, The START Center for Cancer Care. conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 7 clinical trials were completed, i.e. on average, 18.4% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 5 clinical trials were completed. i.e. 26.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The START Center for Cancer Care." #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Ascentage Pharma Group Inc." with 3 trials sponsored, "Compugen Ltd" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Incyte Corporation" with 2 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The START Center for Cancer Care." #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "California Institute for Regenerative Medicine (CIRM)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "The START Center for Cancer Care." are "Solid Tumor" (10 trials), "Advanced Solid Tumor" (6 trials), "Ovarian Cancer" (5 trials), "Breast Cancer" (4 trials) and "Neoplasms" (4 trials). Many other conditions were trialed in "The START Center for Cancer Care." in a lesser frequency.

Most popular intervention types in "The START Center for Cancer Care." are "Drug" (46 trials), "Biological" (3 trials), "Combination Product" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (7 trials), "Gemcitabine" (5 trials), "Cetuximab" (2 trials), "Docetaxel" (2 trials) and "Entinostat" (2 trials). Other intervention names were less common.

The vast majority of trials in "The START Center for Cancer Care." are 42 trials for "All" genders, 5 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "The START Center for Cancer Care.". undefined are not yet recruiting, 15 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in The START Center for Cancer Care., 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in The START Center for Cancer Care., 37 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".